(The Hill) — The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 ...

Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investing.com – Jefferies hat das Kursziel für Ironwood Pharmaceuticals (NASDAQ:IRWD) von 0,70 $ auf 3,70 $ angehoben, die Einstufung jedoch auf "Hold" belassen. Das Analysehaus erhöhte seine ...

Investing.com - Jefferies raised its price target on Ironwood Pharmaceuticals (NASDAQ:IRWD) to $3.70 from $0.70 while maintaining a Hold rating on the stock. The firm increased its Linzess peak sales ...

Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in recent quarters. The company markets Linzess in the United States in ...

Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, ...

We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent ...